Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence.

Bergerot P, Lamb P, Wang E, Pal SK.

Mol Cancer Ther. 2019 Dec;18(12):2185-2193. doi: 10.1158/1535-7163.MCT-18-1399. Review.

PMID:
31792125
2.

Distress and Quality of Life Among Patients with Advanced Genitourinary Cancers.

Bergerot CD, Philip EJ, Bergerot PG, Pal SK.

Eur Urol Focus. 2019 Nov 8. pii: S2405-4569(19)30336-0. doi: 10.1016/j.euf.2019.10.014. [Epub ahead of print]

PMID:
31711933
3.

First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options.

Loo V, Salgia M, Bergerot P, Philip EJ, Pal SK.

Target Oncol. 2019 Dec;14(6):639-645. doi: 10.1007/s11523-019-00676-y. Review.

PMID:
31595385
4.

Obesity and psychosocial well-being among cancer patients and survivors.

Philip EJ, Bergerot CD, Clark K, Bergerot P, Loscalzo M.

Psychooncology. 2019 Nov;28(11):2141-2148. doi: 10.1002/pon.5181. Epub 2019 Sep 4.

PMID:
31486137
5.

Association between chemotherapy toxicity risk scores and physical symptoms among older Brazilian adults with cancer.

Bergerot CD, Razavi M, Philip EJ, Bergerot PG, Soto-Perez-de-Celis E, De Domenico EBL, Clark KL, Loscalzo M, Pal SK, Dale W.

J Geriatr Oncol. 2019 Aug 8. pii: S1879-4068(19)30191-2. doi: 10.1016/j.jgo.2019.07.006. [Epub ahead of print]

PMID:
31401205
6.

The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions.

Salgia NJ, Dara Y, Bergerot P, Salgia M, Pal SK.

Curr Treat Options Oncol. 2019 Apr 1;20(5):41. doi: 10.1007/s11864-019-0638-1. Review.

PMID:
30937639
7.

Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy.

Bergerot CD, Bergerot PG, Philip EJ, Hsu JA, Dizman N, Vaishampayan U, Dorff T, Pal SK.

J Immunother Cancer. 2019 Mar 12;7(1):71. doi: 10.1186/s40425-019-0557-5.

8.

Examining Public Communication About Kidney Cancer on Twitter.

Sedrak MS, Salgia MM, Decat Bergerot C, Ashing-Giwa K, Cotta BN, Adashek JJ, Dizman N, Wong AR, Pal SK, Bergerot PG.

JCO Clin Cancer Inform. 2019 Mar;3:1-6. doi: 10.1200/CCI.18.00088.

9.

Patient-reported Outcome Measures in Metastatic Urinary Cancers.

Bergerot CD, Bergerot PG, Philip EJ, Pal SK.

Eur Urol Focus. 2019 Mar 8. pii: S2405-4569(19)30055-0. doi: 10.1016/j.euf.2019.02.020. [Epub ahead of print] Review.

PMID:
30858072
10.

Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma.

Bergerot CD, Battle D, Bergerot PG, Dizman N, Jonasch E, Hammers HJ, George DJ, Bex A, Ljungberg B, Pal SK, Staehler MD.

Front Oncol. 2019 Jan 22;9:11. doi: 10.3389/fonc.2019.00011. eCollection 2019.

11.

A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.

Pal SK, Forero-Torres A, Thompson JA, Morris JC, Chhabra S, Hoimes CJ, Vogelzang NJ, Boyd T, Bergerot PG, Adashek JJ, Li H, Yu X, Gartner EM, Carret AS, Smith DC.

Cancer. 2019 Apr 1;125(7):1124-1132. doi: 10.1002/cncr.31912. Epub 2019 Jan 9.

PMID:
30624766
12.

Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice.

Salgia M, Adashek J, Bergerot P, Pal SK.

Kidney Cancer. 2017 Nov 27;1(2):99-105. doi: 10.3233/KCA-170019. Review.

13.

Assessment of distress and quality of life in rare cancers.

Bergerot CD, Bergerot PG, Philip EJ, De Domenico EBL, Manhaes MFM, Pedras RN, Salgia MM, Dizman N, Ashing KT, Li M, Dale W, Pal SK.

Psychooncology. 2018 Dec;27(12):2740-2746. doi: 10.1002/pon.4873. Epub 2018 Sep 25.

PMID:
30171792
14.

Advances in the Treatment of Metastatic Renal Cell Carcinoma.

Bergerot P, Burns K, Prajapati D, Fox R, Salgia M, Pal SK.

Cancer Treat Res. 2018;175:127-137. doi: 10.1007/978-3-319-93339-9_6.

PMID:
30168120
15.

Adjuvant treatment in renal cell carcinoma.

Dizman N, Adashek JJ, Hsu J, Bergerot PG, Bergerot CD, Pal SK.

Clin Adv Hematol Oncol. 2018 Aug;16(8):555-563. Review.

PMID:
30148828
16.

Biopsychosocial distress and clinical outcome in metastatic renal cell carcinoma.

Bergerot CD, Clark KL, Ashing KT, Bergerot PG, Obenchain R, Dizman N, Hsu J, Philip E, Loscalzo M, Pal SK.

Palliat Support Care. 2019 Jun;17(3):353-355. doi: 10.1017/S1478951518000342. Epub 2018 Jun 18.

PMID:
29911518
17.

Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.

Pal SK, Bergerot P, Dizman N, Bergerot C, Adashek J, Madison R, Chung JH, Ali SM, Jones JO, Salgia R.

Eur Urol. 2018 Jul;74(1):124-128. doi: 10.1016/j.eururo.2018.03.032. No abstract available.

PMID:
29685646
18.

Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients.

Goineau A, Campion L, d'Aillières B, Vié B, Ghesquière A, Béra G, Jaffres D, de Laroche G, Magné N, Artignan X, Chamois J, Bergerot P, Martin E, Créhange G, Deniaud-Alexandre E, Buthaud X, Belkacémi Y, Doré M, de Decker L, Supiot S.

PLoS One. 2018 Apr 9;13(4):e0194173. doi: 10.1371/journal.pone.0194173. eCollection 2018.

19.

The Role of Circulating Tumor DNA in Renal Cell Carcinoma.

Bergerot PG, Hahn AW, Bergerot CD, Jones J, Pal SK.

Curr Treat Options Oncol. 2018 Feb 20;19(2):10. doi: 10.1007/s11864-018-0530-4. Review.

PMID:
29464405
20.

Assessment of Treatment Patterns for Metastatic Renal Cell Carcinoma in Brazil.

Bergerot PG, Bergerot CD, Dizman N, Zequi S, Fay A, Dara Y, Maia MC, Cotta BN, Gonçalves EP, Formiga MN, Tariki MS, Clavijo DA, Choueiri TK, Lopes G, Pal SK.

J Glob Oncol. 2018 Sep;4:1-8. doi: 10.1200/JGO.17.00113. Epub 2017 Dec 27.

21.

Current systemic therapies for metastatic renal cell carcinoma in older adults: A comprehensive review.

Maia MC, Adashek J, Bergerot P, Almeida L, Dos Santos SF, Pal SK.

J Geriatr Oncol. 2018 May;9(3):265-274. doi: 10.1016/j.jgo.2017.11.011. Epub 2017 Dec 15. Review.

PMID:
29249644
22.

Sarcomatoid Renal Cell Carcinoma: The Apple Doesn't Fall Far from the Tree.

Bergerot P, Agarwal N, Pal SK, Jones J.

Clin Cancer Res. 2017 Nov 1;23(21):6381-6383. doi: 10.1158/1078-0432.CCR-17-2039. Epub 2017 Sep 14.

23.

Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile.

Dizman N, Bergerot P, Bergerot C, Lanman RB, Raymond VM, Banks KC, Jones J, Pal SK.

Eur Urol. 2018 Feb;73(2):308-310. doi: 10.1016/j.eururo.2017.08.006. Epub 2017 Aug 24. No abstract available.

PMID:
28844598
24.

Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden.

Maia MC, Bergerot PG, Dizman N, Hsu J, Jones J, Lanman RB, Banks KC, Pal SK.

Kidney Cancer. 2017 Jul 26;1(1):65-70. doi: 10.3233/KCA-170007.

25.

Case Discussion: Systemic Therapy for Metastatic Renal Cell Carcinoma.

Maia MC, Bergerot P, Pal SK.

Eur Urol Focus. 2016 Dec 15;2(6):579-581. doi: 10.1016/j.euf.2017.02.008. Epub 2017 Mar 1.

PMID:
28723488
26.

Quality Oncology Practice Initiative Can Guide and Improve Oncology Providers' Training in Brazil.

Bergerot CD, Philip EJ, Bergerot PG, Elias S, Guimarães DP, Forones NM, Baiocchi OCCG, Batista NA, De Domenico EBL.

J Glob Oncol. 2016 Sep 21;3(3):189-193. doi: 10.1200/JGO.2016.006148. eCollection 2017 Jun.

27.

Developing a Clear Path Forward for Non-Clear-Cell Renal Carcinoma.

Pal SK, Karam JA, Bergerot P, Agarwal N.

J Clin Oncol. 2016 Nov 10;34(32):3825-3826. doi: 10.1200/JCO.2016.69.3572. No abstract available.

PMID:
27601540
28.

Renal cell carcinoma: An update for the practicing urologist.

Pal SK, Bergerot P, Figlin RA.

Asian J Urol. 2015 Jan;2(1):19-25. doi: 10.1016/j.ajur.2015.04.012. Epub 2015 Apr 16. Review.

29.

Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma.

Pal SK, Hsu J, Hsu S, Hu J, Bergerot P, Carmichael C, Saikia J, Liu X, Lau C, Twardowski P, Figlin RA, Yuh BF.

J Geriatr Oncol. 2013 Apr;4(2):128-33.

30.

Preoperative therapy for localized prostate cancer: a comprehensive overview.

Hu J, Hsu J, Bergerot PG, Yuh BE, Stein CA, Pal SK.

Maturitas. 2013 Jan;74(1):3-9. doi: 10.1016/j.maturitas.2012.10.012. Epub 2012 Nov 14. Review.

31.

Tivozanib: current status and future directions in the treatment of solid tumors.

Pal SK, Bergerot PG, Figlin RA.

Expert Opin Investig Drugs. 2012 Dec;21(12):1851-9. doi: 10.1517/13543784.2012.733695. Epub 2012 Sep 26. Review.

32.

Transverse sinus thrombosis associated with otitis media and mastoiditis.

Santos VM, Oliveira ER, Barcelos MS, Figueiredo NC, Santos FH, Bergerot PG.

J Coll Physicians Surg Pak. 2012 Jul;22(7):470-2. doi: 07.2012/JCPSP.470472.

PMID:
22747873
33.

[Ten years of reflection around the announcement of cancer: from the patients questions to implementation].

Bergerot P, Rodde-Dunet MH.

Bull Cancer. 2010 Oct;97(10):1195-6. French. No abstract available.

34.

Concomitant radiochemotherapy or accelerated radiotherapy: analysis of two randomized trials of the French Head and Neck Cancer Group (GORTEC).

Bourhis J, Calais G, Lapeyre M, Tortochaux J, Alfonsi M, Sire C, Bardet E, Rives M, Bergerot P, Rhein B, Desprez B; French Head and Neck Cancer Group (GORTEC).

Semin Oncol. 2004 Dec;31(6):822-6. Review.

PMID:
15599861
35.

[Refining the French system of cost assessment for oncology patients following chemotherapy].

Lévy-Piedbois C, Borella L, Bergerot P, Peuvrel P, Erard C, Parmentier G, Ravaud A, Trombert Paviot B, Armand JP, Rodrigues JM.

Bull Cancer. 2003 Nov;90(11):989-96. French.

36.

Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma.

Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Calais G.

J Clin Oncol. 2004 Jan 1;22(1):69-76. Epub 2003 Dec 2.

PMID:
14657228
37.

Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems.

Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Calais G.

Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):93-8.

PMID:
12504040
38.

[Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy].

Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P.

Bull Cancer. 2000 Aug;87 Spec No:48-53. French.

PMID:
11082723
39.

Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma.

Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P.

J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6.

PMID:
10601378
40.

Final results of a randomized trial comparing chemotherapy plus radiotherapy with chemotherapy plus surgery plus radiotherapy in locally advanced resectable hypopharyngeal carcinomas.

Beauvillain C, Mahé M, Bourdin S, Peuvrel P, Bergerot P, Rivière A, Vignoud J, Deraucourt D, Wesoluch M.

Laryngoscope. 1997 May;107(5):648-53.

PMID:
9149168

Supplemental Content

Loading ...
Support Center